Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
NEW YORK, NY / ACCESSWIRE / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to investors. On that day, Vertex Pharmaceuticals is projected to report earnings of $4 per share, which would ...
Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.
Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.
Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ ...
What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...
Vertex offers up to $70,000 in fertility services assistance for patients undergoing Casgevy treatment. HHS claims Vertex’s program incentivizes patients to choose its gene therapy over competitors.
Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the ...